These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19271940)

  • 1. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
    Longbrake EE; Racke MK
    Expert Rev Neurother; 2009 Mar; 9(3):319-21. PubMed ID: 19271940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
    Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-12, interleukin-23, and psoriasis: current prospects.
    Torti DC; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
    Kasper LH; Everitt D; Leist TP; Ryan KA; Mascelli MA; Johnson K; Raychaudhuri A; Vollmer T;
    Curr Med Res Opin; 2006 Sep; 22(9):1671-8. PubMed ID: 16968570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis.
    Harbige LS; Sharief MK
    Br J Nutr; 2007 Oct; 98 Suppl 1():S46-53. PubMed ID: 17922959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
    Ding C; Xu J; Li J
    Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP; Bonzano L; Roccatagliata L; Cutter GR; Mancardi GL; Bruzzi P
    Ann Neurol; 2009 Mar; 65(3):268-75. PubMed ID: 19334061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Briakinumab.
    Lima XT; Abuabara K; Kimball AB; Lima HC
    Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis.
    Martin R
    Lancet Neurol; 2008 Sep; 7(9):765-6. PubMed ID: 18702995
    [No Abstract]   [Full Text] [Related]  

  • 13. Alternatives to randomized clinical trials.
    Ellison GW; Mickey MR; Myers LW
    Neurology; 1988 Jul; 38(7 Suppl 2):73-5. PubMed ID: 3290718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases.
    Wittig BM
    Curr Opin Investig Drugs; 2007 Nov; 8(11):947-54. PubMed ID: 17979029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population.
    Smith CH; Waubant E; Langer-Gould A
    J Neuroophthalmol; 2009 Jun; 29(2):104-6. PubMed ID: 19491632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclizumab treatment for multiple sclerosis.
    Kim SE
    Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis.
    Petersen T; Møller-Larsen A; Thiel S; Brudek T; Hansen TK; Christensen T
    J Neuroimmunol; 2009 Oct; 215(1-2):108-16. PubMed ID: 19766328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?
    Cohen JA
    Nat Clin Pract Neurol; 2008 Nov; 4(11):588-9. PubMed ID: 18852726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial.
    Somers CC; Ahmad N; Mejias A; Buckingham SC; Carubelli C; Katz K; Leos N; Gomez AM; DeVincenzo JP; Ramilo O; Jafri HS
    Pediatr Allergy Immunol; 2009 Aug; 20(5):477-85. PubMed ID: 19397752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.